Choose the laboratory-facing action

First response: rank the evidence before naming an action. The patient has new hypertension plus proteinuria, so the pattern supports preeclampsia by the stated clinical criteria. The platelet count is abnormal but does not cross the stated severe-feature threshold. The creatinine, transaminases, and hemolysis evidence do not establish a laboratory severe feature at this draw.

Next, apply the supplied ratio card rather than a general biomarker rule. This patient is hospitalized, has a singleton pregnancy and hypertensive disorder, and is 29 weeks 2 days, so the case falls within the stated Elecsys population and window. The 34.7 result is at or below 38. In the PROGNOSIS population, that supports a one-week rule-out claim, while the FDA-cleared device claim is risk assessment for severe features within two weeks.

The defensible laboratory action is to release verified results, ensure routine referral, and use the local critical-result policy for any triggered value. State that the ratio does not diagnose or exclude the clinical condition. If clinical severity and results remain discordant, use the local escalation pathway rather than substituting the ratio for clinical judgment. Communicate the critical finding defined by local policy and document the recipient, time, and read-back when local procedure requires it.